EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Diagnostic Accuracy of LiquidArray MTB-XDR VER 1.0 for the Detection of Mycobacterium tuberculosis Complex, Fluoroquinolone, Amikacin, Ethambutol, and Linezolid Susceptibility

Erick Auma iD, Rencia Alberts iD, Brigitta Derendinger iD, Rouxjeane Venter iD, Elizabeth M Streicher iD, Samantha Pillay iD, Yonas T Ghebrekristos iD, Moses Mburu iD, Morten Ruhwald iD, Robin Warren iD, Adam Penn-Nicholson iD, Grant Theron iD und 1 weitere

Clinical Infectious Diseases · 2025

DOI: 10.1093/cid/ciae614 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2025. Verfasst von Erick Auma und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Science, Technology and Innovation - National Research Foundation, Centre of Excellence for Biomedical Tuberculosis Research, South Afr…. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Antitubercular Agents, Tuberculosis, Multidrug-Resistant. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: EDCTP2 programme, NIBIB NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Drug susceptibility testing (DST) is essential for starting people on effective tuberculosis (TB) regimens. No published data exist for the high-throughput LiquidArray MTB-XDR (LA-XDR) test, which detects Mycobacterium tuberculosis complex (MTBC) and fluoroquinolone, amikacin, ethambutol, and linezolid susceptibility (the latter 2 have no rapid DSTs available).

Methods

We enrolled people (N = 720) with presumptive TB who provided 2 sputum samples for an Xpert MTB/RIF Ultra assay and a culture (MTBC reference standard). Phenotypic DST and Sanger sequencing were the composite reference standards. LA-XDR on the manual FluoroLyse and automated GenoXtract fleXT (fleXT) DNA extraction methods were compared.

Results

For MTBC, LA-XDR had similar sensitivities (85%–87%) and specificities (99%) using each extraction method. Drug susceptibility sensitivities (95% confidence interval) varied: 94% (86%–98%) for fluoroquinolones, 64% (45%–80%) for amikacin, and 88% (79%–93%) for ethambutol (specificities of 97%–100%). Six of 7 (86%) resistant linezolid isolates were detected. LA-XDR with fleXT had indeterminate proportions of 21/251 (8%), 2/251 (1%), 63/251 (25%), and 93/251 (37%) for fluoroquinolones, ethambutol, amikacin, and linezolid, respectively (amikacin and linezolid indeterminates were higher with FluoroLyse-extracted DNA). In a hypothetical population of 100 smear-negative people with fluoroquinolone-resistant TB undergoing fleXT DNA extraction, 25 (25%) would be missed (1 extraction error, 2 invalid results, 15 MTBC-negative, 6 fluoroquinolone-indeterminate, and 1 false-susceptible).

Conclusions

LA-XDR met the minimum World Health Organization target product profile for a next-generation, sputum-based, moderate-complexity DST with high fluoroquinolone and ethambutol resistance sensitivity, moderate amikacin resistance sensitivity, and promise for linezolid resistance, for which more data are needed. Improved LA-XDR MTBC detection would reduce missed resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycobacterium tuberculosisAntitubercular AgentsTuberculosis, Multidrug-ResistantHumansMicrobial Sensitivity TestsLinezolidAmikacinMaleFemaleSensitivity and SpecificityEthambutolFluoroquinolonesAdultMiddle AgedSputumAgedDrug Resistance, Multiple, BacterialYoung Adult

Stichwörter der Autor:innen

LiquidArray MTB-XDRdrug susceptibility testingfluoroquinolonesmolecular diagnosticstuberculosis

Substanzen

Antitubercular AgentsLinezolidAmikacinEthambutolFluoroquinolones

Autor:innen und Institutionen

  • Department of Science, Technology and Innovation - National Research Foundation, Centre of Excellence for Biomedical Tuberculosis Research, South African Medical Research Council Centre for Molecular and Cellular Biolog…
  • National Health Laboratory Service, Greenpoint Tuberculosis Laboratory, Cape Town, South Africa.
  • Tuberculosis Programme, FIND, Geneva, Switzerland.

ORCID-Profile: Erick Auma, Rencia Alberts, Brigitta Derendinger, Rouxjeane Venter, Elizabeth M Streicher, Samantha Pillay, Yonas T Ghebrekristos, Moses Mburu, Morten Ruhwald, Robin Warren, Adam Penn-Nicholson, Grant Theron, Margaretha de Vos

Förderung

  • EDCTP2 programme
  • NIBIB NIH HHS
  • NIH HHS
  • NIAID NIH HHS
  • FIC NIH HHS
  • German Federal Ministry of Education and Research
  • National Institutes of Health

Zitieren

APA

Auma, E., Alberts, R., Derendinger, B., Venter, R., Streicher, E. M., Pillay, S., Ghebrekristos, Y. T., Mburu, M., Ruhwald, M., Warren, R., Penn-Nicholson, A., Theron, G., & de Vos, M. (2025). Diagnostic Accuracy of LiquidArray MTB-XDR VER 1.0 for the Detection of Mycobacterium tuberculosis Complex, Fluoroquinolone, Amikacin, Ethambutol, and Linezolid Susceptibility. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae614

Vancouver

Auma E, Alberts R, Derendinger B, Venter R, Streicher EM, Pillay S, et al. Diagnostic Accuracy of LiquidArray MTB-XDR VER 1.0 for the Detection of Mycobacterium tuberculosis Complex, Fluoroquinolone, Amikacin, Ethambutol, and Linezolid Susceptibility. Clinical Infectious Diseases. 2025. doi:10.1093/cid/ciae614

BibTeX
@article{Auma2025,
  author = {Auma, Erick and Alberts, Rencia and Derendinger, Brigitta and Venter, Rouxjeane and Streicher, Elizabeth M and Pillay, Samantha and Ghebrekristos, Yonas T and Mburu, Moses and Ruhwald, Morten and Warren, Robin and Penn-Nicholson, Adam and Theron, Grant and de Vos, Margaretha},
  title = {Diagnostic Accuracy of LiquidArray MTB-XDR VER 1.0 for the Detection of Mycobacterium tuberculosis Complex, Fluoroquinolone, Amikacin, Ethambutol, and Linezolid Susceptibility},
  journal = {Clinical Infectious Diseases},
  year = {2025},
  doi = {10.1093/cid/ciae614}
}
Kostenlos starten →